A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group Aberrant Methylation of Tumor Suppressor Genes (TSG) In Myeloma Multiple (MM) and Chronic Lymphocytic Leukemia (CLL) Aberrant Methylation of Tumor Suppressor Genes (TSG) In Myeloma Multiple (MM) and Chronic Lymphocytic Leukemia (CLL) Acute Lymphoblastic Leukemia (ALL): Detection of Prognostically Significance Fusion-Genes By Multiplex-Polymerase Chain Reaction (M-PCR) Acute Myeloid Leukemia in the Elderly, Intensive or Maintenance Therapy? Our Experience in Patients Over 65 Years Acute Myeloid Leukemia in the Elderly, Intensive or Maintenance Therapy? Our Experience in Patients Over 65 Years Acute Promyelocytic Leukemia (APL): Genetic Characterization of 78 Argentinian And Uruguayan Patients Acute Promyelocytic Leukemia, Twelve Years Experience at the University Hospital,San Juan, Puerto Rico Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease Allogeneic Stem Cell Transplant with TBI/CY/Cytarabine Conditioning for Childhood Philadelphia-Positive ALL Analysis of 511 Lymphoma Cases in Uruguay Correlation Between the Uptake of Tc-99m-sesta MIBI and Prognostic Factors in Patients with Multiple Myeloma Cutaneous Lymphomas: Experience of a single institution in Lima-Perú Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib and Prognosis Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 Patients from the Nordic Area Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 Patients from the Nordic Area Expression of CD56 As A Prognostic Factor in Multiple Myeloma FLT3 gene internal tandem duplication (ITD) mutations in patients with acute myeloid leukemia (AML) Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report In Vitro CD4+ T Cells Expansion: Induction of Regulatory T Cells with Sirolimus and CD3/CD28 Dynabeads Molecular Evaluation of Telomere length in patients with mantle cell lymphoma (MCL) Monitoring Response to Imatinib By Fluorescence In Situ Hibridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) In Chronic Myeloid Leukemia (CML) Patients (PTS) In Chronic Phase (CP): Experience of Argentina and Uruguay Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia (ALL). Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance (MGUS): Experience of One Institution Prognostic Value of CD38 Expression by Fluorescence Intensity Histogram in Chronic Lymphocytic Leukemia Prognostic Value of CD38 Expression by Fluorescence Intensity Histogram in Chronic Lymphocytic Leukemia Prognostic Value of Different Profiles of the Early Response to Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Results in the Treatment With Chemotherapy in Acute Myeloid Leukemias. Experience of 20 Years Results of the "Mexican method" to conduct allogeneic hematopoietic stem cell transplantation Safety of Intrathecal Rituximab as Prophylaxis or Treatment in CD20+ Acute Lymphoblastic Leukemia (ALL) and Aggressive Lymphoma (AL): Report from a Mexican Pilot Study siRNA-Inhibition OF E2A-PBX1 in Pre-B Leukemia Cells Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL): A Single Centre Experience

Blogs

Is Ayurveda the Answer to Women’s Health Issues?
by The 4Wholeness Team
September 01, 2015

Related News

Inform Dual ISH test determines if breast cancer patients are candidates for trastuzumab

Jun 16, 2011

Inform Dual ISH test determines if breast cancer patients are candidates for trastuzumab


A total of 64 percent of global asbestos use attributable to Asia from years 2001 to 2007

Jun 24, 2011

A total of 64 percent of global asbestos use attributable to Asia from years 2001 to 2007


The number increased from 9.8 million in 2001 to almost 12 million in 2007

Mar 11, 2011

The number increased from 9.8 million in 2001 to almost 12 million in 2007